Skip to main content
menu
Wilmot Cancer Institute / Cancers We Treat / Lymphomas / Your Team

Paul M. Barr, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 784-7907

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

James P. Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642

Faculty Appointments

Patient Care Settings

Cancer, Hematology & Oncology

Biography

As the Director of the Clinical Trials Office for Wilmot Cancer Institute, I oversee our state-of-the-art clinical trials while also educating my patients about their disease so they are as informed as possible. This enables my patients to participate in the process of making the best treatment decisions.

Individual patients drew me into the field of hematology/oncology. I am driven by the desire to develop better, less toxic treatments for our lymphoma and leukemia patients. I also have an amazing team working with me that is focused on communicating with and educating our patients, helping them in every aspect of their lives.

If I were to recommend one thing to patients, it would be to ask about clinical trials. While a clinical trial may not be appropriate in every circumstance, all patients should learn about these important options.

Conditions I Treat

- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Chronic lymphocytic leukemia

Professional Background

Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Research

Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.

Credentials

Specialties

    Education

    2000
    MD | Northeast Ohio Medical University

    Post-doctoral Training & Residency

    07/01/2004 - 06/30/2007
    Fellowship in Hematology & Oncology at University Hospitals Cleveland Medical Center

    07/01/2001 - 06/30/2003
    Residency in Internal Medicine at University Hospitals Cleveland Medical Center

    07/01/2000 - 06/30/2001
    Internship in Internal Medicine at University Hospitals Cleveland Medical Center

    VIEW ALL expand_more

    Awards

    2012 - 2015
    Lymphoma Research Foundation Clinical Investigator

    2011 - 2015
    NIH Loan Repayment Program Award Recipient
    Sponsor: NIH

    2011 - 2014
    Wilmot Cancer Research Fellowship

    2009
    American Society of Hematology Clinical Research Training Institute

    2008
    NIH/NCI K12 Paul Calabresi Scholar
    Sponsor: NIH
    Location: University Hospitals Case Medical Center, Case Western Reserve

    2006 - 2007
    John W. Harris, MD Hematology Scholar Award
    Location: Case Western Reserve University

    2003 - 2004
    Chief Medical Resident
    Location: Case Western Reserve University/University Hospitals

    1996
    Department of Zoology Honors Program

    1996
    Phi Beta Kappa

    1995
    Howard Hughes Summer Scholars Program

    1995
    Miami MED Premedical Honorary

    VIEW ALL expand_more

    Clinical Trials

    First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

    Lead Researcher: Paul M Barr

    Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: third line or later of treatment (3L) + chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101 and a dose expansion phase to determine the change in disease activity in participants with CLL or non-GCB DLBCL. Approximately 128 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide. In the Dose Escalation phase of the study participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 60 month study duration. In the dose expansion phase of the study participants receive oral ABBV-101, as part of the approximately 60 month study duration . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

    View Study Details

    Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study,Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

    Lead Researcher: Paul M Barr

    This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.

    View Study Details

    Publications

    Journal Articles

    1/12/2024
    Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger SM, Owen C, Kuzma C, Abramson JS, Little RF, Dinner SN, Stone RM, Uy GL, Stock W, Mandrekar SJ, Byrd JC. "Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL." Blood.. 2024 Jan 12; Epub 2024 Jan 12.

    12/16/2023
    Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Qureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SM, Stephens DM, Bachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzmán A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, Bi C, . "Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium." Journal of hematology & oncology.. 2023 Dec 16; 16(1):122. Epub 2023 Dec 16.

    12/7/2023
    El Hussein S, Fang H, Jelloul FZ, Wang W, Loghavi S, Miranda RN, Friedberg JW, Burack WR, Evans AG, Xu J, Medeiros LJ. "T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features." Archives of pathology & laboratory medicine.. 2023 Dec 7; Epub 2023 Dec 07.

    Books & Chapters

    2019
    Book Title: How I treat early relapsing follicular lymphoma
    Author List: Casulo C, Barr PM
    Published By: Blood 2019

    2019
    Book Title: Augmenting Indolent Lymphoma Treatment Options with the Combination of Lenalidomide and Rituximab.
    Author List: Barr PM
    Published By: J Clin Oncology 2019

    2018
    Book Title: Pitfalls of Combining Novel Agents in Lymphoma
    Author List: Rodgers TD; Barr PM
    Published By: Current treatment options in oncology 2018

    VIEW ALL PUBLICATIONS

    Reviews

    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.